Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose

Katherine B. Philips, Metin Kurtoglu, Howard J. Leung, Huaping Liu, Ningguo Gao, Mark A. Lehrman, Timothy G. Murray, Theodore Lampidis

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods: From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results: Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions: Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.

Original languageEnglish
Pages (from-to)349-361
Number of pages13
JournalCancer Chemotherapy and Pharmacology
Volume73
Issue number2
DOIs
StatePublished - Jan 1 2014

Fingerprint

Glycogen Phosphorylase
Starvation
Tumor Cell Line
Tumors
Protein Isoforms
Down-Regulation
Cells
Glucose
Cell Line
Metabolic Networks and Pathways
Glycosylation
Unfolded Protein Response
Tunicamycin
Neoplasms

Keywords

  • 2-Deoxy-d-glucose
  • Glucose starvation
  • Glycogen
  • Unfolded protein response

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose. / Philips, Katherine B.; Kurtoglu, Metin; Leung, Howard J.; Liu, Huaping; Gao, Ningguo; Lehrman, Mark A.; Murray, Timothy G.; Lampidis, Theodore.

In: Cancer Chemotherapy and Pharmacology, Vol. 73, No. 2, 01.01.2014, p. 349-361.

Research output: Contribution to journalArticle

Philips, Katherine B. ; Kurtoglu, Metin ; Leung, Howard J. ; Liu, Huaping ; Gao, Ningguo ; Lehrman, Mark A. ; Murray, Timothy G. ; Lampidis, Theodore. / Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose. In: Cancer Chemotherapy and Pharmacology. 2014 ; Vol. 73, No. 2. pp. 349-361.
@article{b911ad425515482c88537a6bf6a3a2ea,
title = "Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose",
abstract = "Background: As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods: From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results: Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions: Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.",
keywords = "2-Deoxy-d-glucose, Glucose starvation, Glycogen, Unfolded protein response",
author = "Philips, {Katherine B.} and Metin Kurtoglu and Leung, {Howard J.} and Huaping Liu and Ningguo Gao and Lehrman, {Mark A.} and Murray, {Timothy G.} and Theodore Lampidis",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00280-013-2358-8",
language = "English",
volume = "73",
pages = "349--361",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-d-glucose

AU - Philips, Katherine B.

AU - Kurtoglu, Metin

AU - Leung, Howard J.

AU - Liu, Huaping

AU - Gao, Ningguo

AU - Lehrman, Mark A.

AU - Murray, Timothy G.

AU - Lampidis, Theodore

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods: From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results: Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions: Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.

AB - Background: As tumors evolve, they upregulate glucose metabolism while also encountering intermittent periods of glucose deprivation. Here, we investigate mechanisms by which pancreatic cancer cells respond to therapeutic (2-deoxy-d-glucose, 2-DG) and physiologic (glucose starvation, GS) forms of glucose restriction. Methods: From a tumor cell line (1420) that is unusually sensitive to 2-DG under normoxia, low (14DG2)- and high (14DG5)-dose resistant cell lines were selected and used to probe the metabolic pathways involved with their response to different forms of glucose deprivation. Results: Muted induction of the unfolded protein response was found to correlate with resistance to 2-DG. Additionally, 14DG2 displayed reduced 2-DG uptake, while 14DG5 was cross-resistant to tunicamycin, suggesting it has enhanced ability to manage glycosylation defects. Conversely, 2-DG-resistant cell lines were more sensitive than their parental cell line to GS, which coincided with lowered levels of glycogen phosphorylase (PYGB) and reduced breakdown of glycogen to glucose in the 2-DG-resistant cell lines. Moreover, by inhibiting PYGB in the parental cell line, sensitivity to GS was increased. Conclusions: Overall, the data demonstrate that the manner in which glucose is restricted in tumor cells, i.e., therapeutic or physiologic, leads to differential biological responses involving distinct glucose metabolic pathways. Moreover, in evolving tumors where glucose restriction occurs, the identification of PYGB as a metabolic target may have clinical application.

KW - 2-Deoxy-d-glucose

KW - Glucose starvation

KW - Glycogen

KW - Unfolded protein response

UR - http://www.scopus.com/inward/record.url?scp=84896040133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896040133&partnerID=8YFLogxK

U2 - 10.1007/s00280-013-2358-8

DO - 10.1007/s00280-013-2358-8

M3 - Article

VL - 73

SP - 349

EP - 361

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -